Women's Health Nursing (여성건강간호학회지)

Korean Society of Women Health Nursing (한국여성건강간호학회)
권호 표지
DOI QR코드

DOI QR Code

Characteristics and Quality of Life in Gynecologic Cancer Patients with Chemotherapy-induced Peripheral Neuropathy

부인암 환자의 말초신경병증과 삶의 질

  • Received : 2013.08.27
  • Accepted : 2013.12.02
  • Published : 2013.12.20
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of this study was to identify chemotherapy induced peripheral neuropathy, quality of life of patients with gynecologic cancer. Methods: This was a cross-sectional survey design. We collected 130 patients with gynecologic cancer. They complete a self reported questionnaire including items related neuropathy and quality of life (FACT-GOG/Ntx subscale, FACT-G scale). Results: The neuropathy score was $14.3{\pm}7.9$. The quality of life score was $64.8{\pm}16.4$. The neuropathy induced significant difference according to diabetic status, difficulties in performing household chores and willing to discontinuity of chemotherapy. And duration of cancer diagnosis, neuropathy, number of total chemo agent associated with quality of life. There was a negative correlation between number of total chemo agent and quality of life. Neuropathy independently affected quality of life. Conclusion: Chemotherapy induced peripheral neuropathy of patients with gynecologic cancer adversely affected women's quality of life and activities of daily living. To improve patient's quality of life, it is important that accurate assess and appropriately manage neuropathy in patients with gynecologic cancer.

Keywords

References

  1. Bakitas, M. A. (2007). Background noise: The experience of chemotherapy- induced peripheral neuropathy. Nursing Research, 56, 323-331. http://dx.doi.org/10.1097/01.nnr.0000 289503.22414.79
  2. Bartlett, J. E., Kotrlik, J. W., & Higgins, C. C. (2001). Organizational research: Determining appropriate sample size in survey research. Information Technology, Learning, and Performance Journal, 19, 43-50.
  3. Berek, J. S. (2007). Berek & Novak's Gynecology (14ed.). Philadelphia: Lippincott.
  4. Calhoun, E. A., Welshman, E. E., Chang, C. H., Lurain, J. R., Fishman, D. A., Hunt, T. L., et al. (2003). Psychometric evaluation of functional assessment of cancer therapy/gynecologic oncology group-neurotoxicity(FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. International Journal of Gynecologic Oncology, 13, 741-748. https://doi.org/10.1111/j.1525-1438.2003.13603.x
  5. Cella, D. (1997). Manual of the functional assessment of chronic illness therapy (FACIT) measurement system. Evanston, IL: Center on outcomes, research and education (CORE), Evanston Northwestern Healthcare and Northwestern University.
  6. Hausheer, F. H., Schilsky, R. L., Bain, S., Berghorn, E. J., & Lieberman, F. (2006). Diagnosis, management, and evaluation of chemotherapy induced peripheral neuropathy. Seminars in Oncology, 33, 15-49.
  7. Kaley, T. J., & Deangelis, L. M. (2009). Therapy of chemotherapyinduced peripheral neuropathy. British Journal of Haematology, 145, 3-14. http://dx.doi.org/10.1111/j.1365-2141.2008. 07558.x
  8. Kim, H. M. (2012). Symptoms and relief therapy related to chemotherapy induced peripheral neuropathy in patients with cancer. Unpublished master's thesis, Keimyoung University, Daegu.
  9. Kim, J. H., Choi, K. S., Kim, T. W., & Hong, Y. S. (2011). Quality of life in colorectal cancer patients with chemotherapy induced peripheral neuropathy. Journal of Korean Oncology Nursing, 11, 254-262. http://dx.doi.org/10.5388/jkon.2011. 11.3.254
  10. Kiser, D. W., Greer, T. B., Wilmoth, M. C., Dmochowski, J., & Naumann, R. W. (2010). Peripheral neuropathy in patients with gynecologic cancer receiving chemotherapy: Patient reports and provider assessments. Oncology Nursing Forum, 37, 758-764. http://dx.doi.org/10.1188/10.ONF.758-764
  11. Kwak, M. K., Kim, E. J., Lee, E. R., Kwon, I. G., & Hwang, M. S. (2010). Characteristics and quality of life in patients with chemotherapy induced peripheral neuropathy. Journal of Korean Oncology Nursing, 10, 231-239. https://doi.org/10.5388/jkon.2010.10.2.231
  12. Long, H. J., Monk, B. J., Huang, H. Q., Grendys, E. C., Mc- Meekin, D. S., Sorosky, J., et al. (2006). Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A gynecologic oncology group study. Gynecologic Oncology, 100, 537-543. https://doi.org/10.1016/j.ygyno.2005.09.023
  13. Mantyh, P. W. (2006). Cancer pain and its impact on diagnosis, survival and quality of life. Nature Reviews Neuroscience, 7, 797-809. https://doi.org/10.1038/nrn1914
  14. Pan, Y., & Kao, M. S. (2007). Discordance of clinical symptoms and electrophysiologic findings in taxane plus platinum-induced neuropathy. International Journal of Gynecological Cancer, 17, 394-397. http://dx.doi.org/10.1111/j.1525-1438. 2006.00766.x
  15. Park, A. R., Kim, S. J., Bang, J. S., & La, H. O. (2009). Oxaliplatininduced peripheral neuropathy in patients with advanced or metastatic gastric cancer. The Korean Journal of Clinical Pharmacy, 19, 18-22.
  16. Rao, R. D., Michalak, J. C., Sloan, J. A., Loprinzi, C. L., Soori, G. S., Nikcevich, D. A., et al. (2007). Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, cross-over trial. Cancer, 110, 2110-2118. http://dx. doi.org/10.1002/cncr.23008
  17. Smith, E. L., Whedon, M. B., & Bookbinder, M. (2002). Quality improvement of painful peripheral neuropathy. Seminars in Oncology Nursing, 18, 36-43. https://doi.org/10.1053/sonu.2002.30043
  18. Smith, E. M., Beck, S. L., & Cohen, J. (2008). The total neuropathy score: A tool for measuring chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum, 35, 96-102. http://dx.doi.org/10.1188/08.ONF.96-102
  19. Statistics Korea. (2010). Cancer occurrence ratio in Korea women. Retrieved July, 15, 2013, from http://kosis.kr/wnsearch/ totalSearch.jsp
  20. Sweeney, C. W. (2002). Understanding peripheral neuropathy in patients with cancer: Background and patients assessment. Clinical Journal of Oncology Nursing, 6, 163-166. https://doi.org/10.1188/02.CJON.163-166
  21. Tofthagen, C. (2010). Patient perceptions associated with chemotherapy- induced peripheral neuropathy. Clinical Journal of Oncology Nursing, 14, E22-E28. http://dx.doi.org/10.1188/ 10.CJON.E22-E28
  22. Tofthagen, C., McAllister, R. D., & McMillan, S. C. (2011). Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clinical Journal of Oncology Nursing, 15 , 182-188. http://dx.doi.org/10.1188/11.CJON.182-188
  23. Verstappen, C. C., Heimans, J. J., Hoekman, K., & Postma, T. J. (2003). Neurotoxic complication of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs, 63, 1549-1563. https://doi.org/10.2165/00003495-200363150-00003
  24. Viens, P., Petit, T., Yovine, A., Bougnoux, P., Deplanque, G., Cottu, P. H., et al. (2006). A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Annuals of Oncology, 17, 429- 436. http://dx.doi.org/10.1093/annonc/mdj097
  25. Wickham, R. (2007). Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clinical Journal of Oncology Nursing, 11 , 361-376. https://doi.org/10.1188/07.CJON.361-376
  26. Wolf, S., Barton, D., Kottschade, L., Grothey, A., & Loprinzi, C. (2008). Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. European Journal of Cancer, 44, 1507-1515. http://dx.doi.org/10.1016/j.ejca.2008. 04.018
  27. Yarbro, C. H., Frogge, M. H., & Goodman, M. (2004). Cancer symptom management (3rd ed.). Boston: Jones and Bartlett.

Cited by

  1. 족욕요법이 항암화학요법을 받은 전이·재발암 환자의 말초신경병증으로 인한 증상강도, 고통정도 및 일상생활 방해정도에 미치는 효과 vol.24, pp.2, 2013, https://doi.org/10.22705/jkashcn.2017.24.2.189
  2. 항암화학요법을 받는 위암 환자의 말초신경병증, 수면 및 삶의 질에 대한 연구 vol.25, pp.3, 2013, https://doi.org/10.7739/jkafn.2018.25.3.176
  3. Structural Equation Modeling of Quality of Life in Patients With Uterine Cancer vol.32, pp.2, 2013, https://doi.org/10.7475/kjan.2020.32.2.109